1. Academic Validation
  2. Discovery of LHRH and development of LHRH analogs for prostate cancer treatment

Discovery of LHRH and development of LHRH analogs for prostate cancer treatment

  • Prostate. 2017 Jun;77(9):1036-1054. doi: 10.1002/pros.23360.
Andrew V Schally 1 2 3 4 5 Norman L Block 2 3 5 Ferenc G Rick 1 6
Affiliations

Affiliations

  • 1 Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, Florida.
  • 2 Department of Pathology, University of Miami Miller School of Medicine, Miami, Florida.
  • 3 Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.
  • 4 Division of Endocrinology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.
  • 5 Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
  • 6 Department of Urology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida.
Abstract

The discovery, isolation, elucidation of structure, synthesis, and initial testing of the neuropeptide hypothalamic luteinizing hormone-releasing hormone (LHRH), which regulates reproduction, is briefly described. The design, synthesis, and experimental and clinical testing of agonistic analogs of LHRH is extensively reviewed focusing on the development of new methods for the treatment of prostate Cancer. Subsequent development of antagonistic analogs of LHRH is then faithfully recounted with special emphasis on therapy of prostate Cancer and BPH. The concepts of targeted therapy to peptide receptors on tumors are re-examined and the development of the cytotoxic analogs of LHRH and their status is reviewed. The endeavor to develop better therapies for prostate Cancer, based on LHRH analogs, guided much of our work.

Keywords

CRPC; advanced prostate cancer; androgen deprivation therapy; luteinizing hormone-releasing hormone; targeted therapy.

Figures
Products